Steady Expansion Forecast for Histone Deacetylase Inhibitors Market, Projected to Reach $1.71 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Histone Deacetylase Inhibitors Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent years, there has been a robust growth in the market size of histone deacetylase inhibitors. The market, which was worth $1.2 billion in 2024, is projected to expand to $1.29 billion in 2025, indicating a compound annual growth rate (CAGR) of 7.2%. This growth during the historical period can be credited to factors such as regulatory assistance and rapid approvals, a rising incidence of cancer, amplified investment in cancer research, the broadening of therapeutic applications, as well as an increase in healthcare infrastructure spending.

Histone Deacetylase Inhibitors Market Size Forecast: What's the Projected Valuation by 2029?
In the coming years, a robust growth is anticipated in the histone deacetylase inhibitors market, surging up to "$1.71 billion by 2029 with a compound annual growth rate (CAGR) of 7.2%. The upsurge during the projected period can be credited to increasing investments in biotechnology, a rising aging population, encouraging regulatory approvals, expedited drug approval procedures, bettered drug delivery systems, and broadened therapeutic applications. In the forecast period, prominent trends involve the introduction of wearable devices for patient health tracking, breakthroughs in nanotechnology and drug delivery techniques, progress in identification and verification of biomarkers, the application of artificial intelligence (AI) and machine learning, along with the emergence of next-generation sequencing.

View the full report here:
https://www.thebusinessresearchcompany.com/report/histone-deacetylase-inhibitors-global-market-report

What Are the Drivers Transforming the Histone Deacetylase Inhibitors Market?
The escalating occurrences of cancer are anticipated to fuel the expansion of the histone deacetylase inhibitors market in the future. The primary reasons for the surge in cancer cases include aging populations, greater exposure to risk elements such as tobacco, diet, and environmental pollutants, and advancements in diagnostic methods resulting in earlier and more repeated detections. Histone deacetylase inhibitors combat cancer by modifying the chromatin structure, which activates tumor suppressant genes and inhibits oncogenes, thereby triggering cell cycle stoppage and cell death in cancer cells. For example, in February 2024, as per the World Health Organization, a US-founded intergovernmental organization, roughly 35 million new cancer incidences were projected for 2050, marking a 77% surge from the estimated 20 million cases in 2022. Consequently, the mounting occurrences of cancer are spurring the growth of the histone deacetylase inhibitors market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17170&type=smp

What Long-Term Trends Will Define the Future of the Histone Deacetylase Inhibitors Market?
In an effort to diversify treatment choices and enhance patient suitability and adherence, major corporations in the histone deacetylase inhibitors market are concentrating on the creation of inventive product formulations, such as the oral histone deacetylase (HDAC) inhibitors. The oral HDAC inhibitor, which is consumed orally, is intended to target the HDAC enzymes that are vital for gene regulation and could potentially be utilized in the treatment of an array of illnesses, including cancer and inflammation. For example, in March 2024, Italfarmaco S.p.A., a pharmaceutical company based in Italy, attained FDA approval for Duvyzat (givinostat), an oral HDAC inhibitor used in the treatment of Duchenne muscular dystrophy (DMD) in patients six years old and above. Duvyzat, meant to alleviate the sequence of events leading to muscle damage, could potentially hamper the rapid deterioration of muscles associated with DMD. It accomplishes this by suppressing the overactivity of HDAC, thereby reducing inflammation and fibrosis and encouraging the regeneration of muscle fibers. This approval was achieved on the foundation of the results from the definitive phase 3 EPIDYS trial, which met its primary objective, showing that patients on Duvyzat had a significant reduction in the time taken to complete the four-stair climb assessment as opposed to the placebo.

Which Segments in the Histone Deacetylase Inhibitors Market Offer the Most Profit Potential?
The histone deacetylase inhibitors market covered in this report is segmented -

1) By Classification: Class I Histone Deacetylases (HDACs), Class II Histone Deacetylases (HDACs), Class III Histone Deacetylases (HDACs), Other Classifications
2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
4) By Application: Oncology, Neurology, Other Applications
5) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:
1) By Class I Histone Deacetylases (HDACs): HDAC1 Inhibitors, HDAC2 Inhibitors, HDAC3 Inhibitors, HDAC8 Inhibitors
2) By Class II Histone Deacetylases (HDACs): HDAC4 Inhibitors, HDAC5 Inhibitors, HDAC6 Inhibitors, HDAC7 Inhibitors, HDAC9 Inhibitors, HDAC10 Inhibitors
3) By Class III Histone Deacetylases (HDACs): Sirtuin 1 (SIRT1) Inhibitors, Sirtuin 2 (SIRT2) Inhibitors, Sirtuin 3 (SIRT3) Inhibitors, Sirtuin 4 (SIRT4) Inhibitors, Sirtuin 5 (SIRT5) Inhibitors, Sirtuin 6 (SIRT6) Inhibitors, Sirtuin 7 (SIRT7) Inhibitors
4) By Other Classifications: Dual-acting HDAC Inhibitors, Pan-HDAC Inhibitors, Selective HDAC Inhibitors, Combination Inhibitors (HDAC + Other Mechanisms)

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=17170&type=smp

Which Firms Dominate the Histone Deacetylase Inhibitors Market by Market Share and Revenue in 2025?
Major companies operating in the histone deacetylase inhibitors market are Merck & Co. Inc., AstraZeneca plc, Novartis AG, Eisai Co. Ltd., Aurobindo Pharma Limited, Karyopharm Therapeutics Inc., Syndax Pharmaceuticals Inc., MEI Pharma Inc., Italfarmaco S.p.A., Tokyo Chemical Industry Co. Ltd., InvivoGen Corp., Huya Bioscience International LLC, Crystal Genomics Inc., Spectrum Pharmaceuticals Inc., Curis Inc., Celgene Corporation, Celleron Therapeutics, Medivir AB, Onxeo SA, Regenacy Pharmaceuticals Inc., Shenzhen Chipscreen Biosciences Co. Ltd., Wellness Pharma International LLC, Forum Pharmaceuticals Inc., Midatech Pharma PLC

Which Regions Offer the Highest Growth Potential in the Histone Deacetylase Inhibitors Market?
North America was the largest region in the histone deacetylase inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17170

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.